Glenmark gets US nod for oral contraceptive pills

The approval is for Desogestrel and Ethinyl Estradiol tablets in the strength of 0.15 mg/0.02 mg and for Ethinyl Estradiol tablets in the strength of 0.01 mg

Glenmark Pharmaceuticals said it had received final approval by the US health regulator to market its oral contraceptive Desogestrel and Ethinyl Estradiol tablets in the American market.

Glenmark Generics Inc USA, a subsidiary of Glenmark Generics has been granted final approval for their abbreviated new drug application (ANDA) by the United States Food and Drug Administration (USFDA) for Desogestrel and Ethinyl Estradiol tablets, Glenmark Pharmaceuticals said in a statement.

The company will market their approved product as Viorele TM Tablets and plans to commence shipping immediately, it added.
 
The approval is for Desogestrel and Ethinyl Estradiol tablets in the strength of 0.15 mg/0.02 mg and for Ethinyl Estradiol tablets in the strength of 0.01 mg.

Viorele TM Tablets are generic version of Teva Women's Health Inc Mircette tablets, Glenmark said.

"According to IMS Health for the 12 month period ending December 2011, the total market sales achieved for Desogestrel & Ethinyl Estradiol tablets USP 0.15 mg/0.02 mg and Ethinyl Estradiol Tablets USP 0.01 mg were approximately $98 million," it added.

The company's current portfolio consists of 78 generic products authorised for distribution in the US market and 40 ANDA's pending approval with the USFDA.

In the late afternoon, Glenmark Pharmaceuticals was trading at around Rs308 per share on the Bombay Stock Exchange, 1.05% up from the previous close.

User

BHEL to withdraw initial papers for FPO

BHEL had filed DRHP in September for the FPO under which the government planned to offload 5% stake in the company

State-owned equipment maker BHEL, which will announce annual results on Tuesday, said it would withdraw the initial papers for its follow-on offer that were filed with Securities and Exchange Board of India (SEBI).

"The Board of Directors of BHEL has approved the withdrawal of DRHP (draft red herring prospectus) filed by BHEL with SEBI," the company informed BSE.

The company said the decision has been taken after the receipt of "no-objection" for withdrawal of DRHP for BHEL FPO from the Department of Heavy industry and Department of Disinvestment.

The company filed DRHP in September for the follow-on public offer (FPO) under which the government planned to offload 5% stake in the company.
The sale of government's 5% stake in the power equipment maker was expected to fetch over Rs4,000 crore.

The government in July 2011 had appointed four merchant bankers -- Morgan Stanley, DSP Merrill Lynch (Bank of America), ICICI Securities and Kotak Mahindra Capital -- for BHEL's FPO.

On 30 August 2011, it had approved the disinvestment of 5% of its shareholding in BHEL. The government holds 67.72% stake in the entity.

In the late afternoon, BHEL was trading at around Rs265.05 per share on the Bombay Stock Exchange, 1.82% up from the previous close.

User

Reliance Power commissions fourth 300 MW unit of Rosa plant

According to Reliance Power, the Rosa project is consistently operating at above 95% plant load factor

Reliance Power said it has commissioned the fourth 300 MW unit of the Rosa plant in Uttar Pradesh, taking the project's total operational capacity to 1,200 MW.

The 1,200 MW Rosa thermal power project is now fully operational and the fourth unit was commissioned on 31 March 2012, four months ahead of the schedule of July, the company said.

"Rosa power project is also the first independent thermal power project in North India to be brought online and represents the largest ever private sector investment in Uttar Pradesh with an investment outlay of over Rs 6,000 crore," the company said in a statement.

The third 300 MW unit of the plant was commissioned in December 2011, which was also ahead of schedule. Rosa project has four units, each having capacity of 300 MW.

According to Reliance Power, the project is consistently operating at above 95% plant load factor (PLF). Electricity generated from the plant would be supplied to Uttar Pradesh. Reliance Power CEO J P Chalasani said that Rosa occupies a special place in the company's portfolio as it is their first operating power plant.

"The achievement of our teams in construction and commissioning of the Rosa project is commendable and unmatched in the Indian Power Sector. This experience gives huge confidence for our ongoing and future projects," he noted.
The company said the project would account for more than 15% of Uttar Pradesh's total energy requirement and would light up about 30 lakh households. On Saturday, Reliance Power had commissioned a 40 MW solar plant in Rajasthan. The project, entailing an investment of about Rs700 crore, would generate over 70 million units of clean power.

In the late afternoon, Reliance Power was trading at around Rs121.20 per share on the Bombay Stock Exchange, 0.9% down from the previous close.

User

We are listening!

Solve the equation and enter in the Captcha field.
  Loading...
Close

To continue


Please
Sign Up or Sign In
with

Email
Close

To continue


Please
Sign Up or Sign In
with

Email

BUY NOW

The Scam
24 Year Of The Scam: The Perennial Bestseller, reads like a Thriller!
Moneylife Magazine
Fiercely independent and pro-consumer information on personal finance
Stockletters in 3 Flavours
Outstanding research that beats mutual funds year after year
MAS: Complete Online Financial Advisory
(Includes Moneylife Magazine and Lion Stockletter)